A recent study suggests that a drug approved for the treatment of seizures may also help treat Alzheimer's in people who do ...

A new diagnosis of Alzheimer's or other dementia often spurs a person to move from their home, new research shows.

Alzheimer's disease might damage the brain in two distinct phases, a new study suggests. An early phase that occurs slowly ...

Annovis has limited cash reserves and faces challenges in financing further trials, making the future of Buntanetap uncertain ...

Researchers are investigating whether drugs currently used for diabetes and eye diseases could help to prevent or treat ...

Potomac-based IGC Pharma Inc. Thursday announced enrollment of patients at the Baycrest Academy for Research and Education in ...

On average, patients with Alzheimer disease and related dementias spend $1199.70 per year on out-of-pocket prescription drug costs.

Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...

On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep ...

Annovis faces financial challenges and questionable efficacy in Alzheimer's and Parkinson's trials, risking poor stock ...

That's because, unlike diseases like cystic fibrosis or sickle-cell anaemia, which are caused by a single gene, most ...

Strategic restructuring will support the ongoing launch of the oral postpartum depression drug, Zurzuvae, and extend Sage’s ...